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Introduction
Novel immunotherapies are emerging as an exciting treat-
ment for a variety of haematological and solid malignan-
cies. Chimeric antigen receptor (CAR) T cells and immune 
checkpoint inhibitors (ICPI) are the two classes of treatment 
currently available. Despite very promising oncological out-
comes for these treatments, neurotoxicity has emerged as 
a serious adverse event. With a growing number of onco-
logical indications, clinicians now need to be aware of the 
neurological side effects of these therapies.
CAR T cell therapy involves the genetic engineering, via 
viral transduction, of the patients own T cell population, to 
incorporate antigen-recognition moieties as well as T cell 
activation costimulatory domains. Following apheresis, viral 
transduction and expansion ex vivo, the CAR T cell popula-
tion is re-infused into the patient, which then directs to the 
desired target antigen on the cancer cell surface. The CAR 
T cells are then activated without the need for MHC–epitope 
presentation or antigen presenting cell co-stimulation, with 
the aim of elimination of the cancer. Currently, there are 
two licenced CAR T cell therapies in the US and Europe for 
relapsed or refractory acute lymphoblastic leukaemia and 
B-cell lymphoma. However, it is likely that the indication 
for these therapies will soon expand to include a wide range 
of other malignancies. Following treatment with CAR T 
cells, neurotoxicity affects up to 60% of treated patients and 
commonly presents with encephalopathy, although tremor, 
seizures, and cerebral oedema may also feature. The patho-
genesis of the neurotoxicity remains unclear but enrichment 
of pro-inflammatory cytokines in the central nervous system 
(CNS), endothelial activation, and macrophage activation 
syndrome have all been proposed. Cytokine release syn-
drome (CRS) may also be seen as CAR T cells encoun-
ter their target cells. This clinical syndrome may resemble 
sepsis and can lead to multiple organ failure and death in 
severe cases.
Immune checkpoints are utilised by the body to inhibit 
T-cell activation, maintain self-tolerance and prevent auto-
immunity. However, cancer cells can commandeer this path-
way to evade immune detection. ICPIs act to remove this 
immune brake and as a result increase the T cell response 
against the cancer. Monoclonal antibodies against cytotoxic 
lymphocyte-associated protein 4 (CTLA-4), programmed 
cell death 1 (PD-1) and PD ligand 1 (PD-L1) have been 
the first therapies approved for a variety of malignancies. In 
contrast to treatment with CAR T cells, neurotoxicity related 
to ICPIs is rare, but has wide and varied neurological pres-
entations involving both the peripheral and central nervous 
system. This toxicity is thought to occur as a result of T cell 
activation leading to autoimmune pathology.
Because of the limited clinical experience of using these 
therapies, optimal definitions, grading systems and manage-
ment strategies are still to be fully optimised. This month’s 
journal club outlines three papers that provide further 
descriptions of the neurological side effects of these prom-
ising therapies.
ASTCT consensus grading for cytokine 
release syndrome and neurologic toxicity 
associated with immune effector cells
The assessment and grading of CRS and neurotoxicity 
associated with novel immunotherapy vary across clini-
cal institutions and trials. Historically, different terms have 
been used for similar symptoms with grading systems based 
on the ability to perform functional activities, which may 
not be practical for bedside application. To compare safety 
profiles and develop optimal management, it is therefore of 
importance to develop a standardised grading criteria. In 
this regard, this paper presents expert consensus guidelines 
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supported by the American Society for Transplantation and 
Cellular Therapy (ASTCT).
First, the group defines CRS as “a supraphysiologic 
response following immune therapy that results in the activa-
tion or engagement of endogenous or infused T cells and/or 
other immune effector cells. Symptoms can be progressive, 
must include fever at the onset, and may include hypoten-
sion, capillary leak (hypoxia) and end organ dysfunction”. 
Importantly, they note that other aetiologies for the patient’s 
symptoms must be excluded and that CRS rarely presents 
beyond 14 days after initiation of therapy. The group then 
define 5 grades of CRS, all of which feature fever (≥ 38.0 °C) 
and are dependent on the presence or absence of constitu-
tional symptoms (myalgia, arthralgia, malaise), hypotension 
(including vasopressor requirement) and hypoxia (including 
oxygen requirements). Grade 5 is defined as death due to 
CRS. Although biomarkers were excluded from the defini-
tion and grading of CRS, the authors encourage their use 
(cytokines, CRP, ferritin) to inform future studies.
Neurotoxicity (termed ICANS; immune effector cell-
associated neurotoxicity syndrome) is then defined as “a 
disorder characterised by a pathologic process involving 
the central nervous system following any immune therapy 
that results in the activation or engagement of endogenous 
or infused T cells and/or other immune effector cells. Symp-
toms or signs can be progressive and may include apha-
sia, altered level of consciousness, impairment of cognitive 
skills, motor weakness, seizures and cerebral oedema”. In 
the authors’ grading of ICANS, an immune effector cell-
associated encephalopathy (ICE) score is incorporated, 
which then with the presence or absence of other neurologi-
cal symptoms (level of consciousness, seizures, motor symp-
toms and elevated ICP/cerebral oedema) gives an overall 
ICANS grade.
Comment: this paper robustly sets out the definitions and 
grading criteria for CRS and neurotoxicity associated with 
novel immunotherapies used to treat malignancies. Use of 
this grading system will allow comparison between centres 
and trials and further the knowledge around these treat-
ments. They emphasise that despite the agreed guidelines, 
further data should be collected due to the limited number of 
treated patients across clinical trials. This will then inform 
further clinical guidelines.
Lee et   al .  Biol  Blood Marrow Transplant. 
2019;25(4):625–638.
Clinical presentation, management, 
and biomarkers of neurotoxicity 
after adoptive immunotherapy with CAR T 
cells
This case series details 25 patients who developed CAR 
T-cell-mediated CRS and neurotoxicity following treat-
ment for a variety of haematological malignancies, and 
hepatocellular carcinoma. The overall disease response 
rate after CAR T cell infusion was 84% and median overall 
survival 54.7 weeks. 12/25 developed low-grade (LGNT) 
and 13/25 high-grade neurotoxicity (HGNT) with the 
median time to first symptoms of 5 ± 0.9 days. By the date 
of database cutoff, 8/13 patients with HGNT had died with 
no deaths in the low-grade group.
In those with LGNT, CRS was present in 92% and 
always preceded the onset of neurological symptoms, 
which consisted of encephalopathy (92%), aphasia (50%) 
and tremor (33%). Median duration of symptoms was 
5 ± 1.8  days. All 13 patients with HGNT experienced 
severe encephalopathy, with involuntary movements sug-
gestive of seizure activity or nonepileptic myoclonus 
seen in a majority (77%). Symptoms often remained pre-
sent > 30 days after CAR T-cell infusion or were ended 
by patient death. All HGNT patients developed CRS, 
although neurotoxicity preceded its onset in two patients. 
Both CRP and ferritin levels rose following CAR T-cell 
infusion. Absolute peak concentrations for ferritin were 
significantly more elevated in patients with HGNT com-
pared to those with LGNT and normalised when symptoms 
resolved. Platelet counts were significantly lower at the 
time of CAR T-cell infusion in patients who later devel-
oped HGNT and may be a marker of blood–brain barrier 
disruption.
Of 10 patients who were imaged with brain MRI 
(LGNT n = 2, HGNT = 8) only 2 patients, both with high-
grade symptoms, had new hyperintense lesions situated in 
the periventricular white matter (n = 2), splenium (n = 2) 
and pons (n = 1). EEG was performed on 18 patients (6 
low- and 12 high-grade) with diffuse or frontal background 
slowing present in all. Periodic or rhythmic patterns within 
the ictal–interictal continuum were seen in 50% and 92% 
of low- and high-grade patients, respectively. Manage-
ment for mild neurotoxicity included supportive therapy, 
and tocilizumab (IL-6R monoclonal antibody) for patients 
with CRS. Most patients received levetiracetam either as 
prophylaxis or at first neurologic symptoms with addi-
tional antiepileptics used for abnormal EEG patterns and 
status epilepticus. Dexamethasone was commonly used to 
treat neurotoxicity.
Comment: this paper informs clinicians of the pres-
entation and management of patients with neurotoxicity 
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following CAR T cell therapy. It is important to note that 
HGNT, age > 65 years and a prolonged course of steroids 
(> 10 days) were significant negative markers for overall 
survival and ferritin may be helpful as a biomarker to fol-
low disease course. In addition, steroid use ≥ 7 days did 
not alter outcome when compared with < 7 days of treat-
ment. Further studies will be required to further clarify the 
clinical spectrum of neurotoxicity and decide on optimal 
management, particularly with regard to different products 
as and when they reach the bedside.
Karschnia P et al. Blood. 2019;133:2212–2221.
Neurologic complications of immune 
checkpoint inhibitors
Neurotoxicity following immune checkpoint inhibitors 
(ICPI) is less common than with CAR T cell therapy, with a 
reported incidence of 3.8%, 6.1%, and 12%, respectively, for 
anti-CTLA4 antibodies, anti-PD1 antibodies and when used 
in combination. Most symptoms are considered low-grade 
including headache, dysgeusia, dizziness and paraesthe-
sia. Although high-grade adverse events are only observed 
in < 1% of cases they include a broad range of diseases 
affecting both the central and peripheral nervous systems. 
There are limited data regarding ICPI-related neurotoxicity, 
which this paper tries to address by presenting a retrospec-
tive review of nine patients who experienced neurological 
adverse events following ICPI treatment.
Patients included in this study had a variety of primary 
malignancies: renal cell carcinoma, melanoma, Hodgkin 
lymphoma and glioblastoma. Four patients were treated 
with a combination of checkpoint inhibitors (anti-PD1 and 
anti-CTLA4). Median time to onset of neurotoxicity was 
8 weeks (5 days–19 weeks) with a variety of diagnoses 
observed including meningoencephalitis (n = 2), polyradicu-
litis (n = 2), limbic encephalitis (n = 1), myositis (n = 1), 
ocular myasthenic syndrome (n = 1), reactivated myasthenia 
(n = 1) and cranial polyneuropathy (n = 1). Detailed clinical 
accounts are only given for three patients in the paper.
Following the onset of neurotoxicity, steroids were com-
menced in all patients and ICPI treatment stopped. 6/9 
patients made a full recovery, one patient a partial recovery 
and two patients died. The patient who experienced myositis 
had a partial response to steroids but then died of cardiac 
complications. The patient with a myasthenic syndrome did 
not receive any benefit with steroids or plasmapheresis and 
died of septic shock. Interestingly, this patient had a remote 
history of ocular myasthenia that had not required treatment 
for several years prior to ICPI therapy. In two patients, ICPI 
treatment was recommenced following resolution of neuro-
logical symptoms, with no further adverse events.
Comment: this paper provides an example of the wide 
variety of neurological diseases that can potentially develop 
post ICPI therapy. Because of the rarity of these adverse 
events, the authors recommend making a diagnosis of ICPI-
related neurotoxicity after excluding other potential causes 
including infectious, metabolic, paraneoplastic and neoplas-
tic aetiologies. Although it is difficult to confirm a definitive 
diagnosis, they also emphasise the importance of recognis-
ing neurotoxicity as quickly as possible so that appropriate 
treatment can be initiated. Of note, once steroids have been 
commenced it is recommended that they be slowly tapered 
over 2–3 months due to the long half-life of ICPI therapy. 
Other immunomodulatory and immunosuppressive treat-
ments may be required in steroid-resistant cases.
Fellner et al. J Neurooncol. 2018;137(3):601–609.
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